Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

about

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

Item

http://www.wikidata.org/entity/Q57741141

description

article

@en

im August 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

@en

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

@nl

type

Item

label

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

@en

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

@nl

prefLabel

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

@en

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

@nl

P1476

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

@en

P2093

Eduardo Mysler

http://www.w3.org/2001/XMLSchema#string

Laura Chadwick

http://www.w3.org/2001/XMLSchema#string

Robert J Moots

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab

The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study

A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab.

Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician.

A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoi

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

P2888

s11926-018-0769-6

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S11926-018-0769-6

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sizheng Zhao

P577

2018-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30094742

http://www.w3.org/2001/XMLSchema#string

P921

P932

6097048

http://www.w3.org/2001/XMLSchema#string